We report a case of a 5-year-old girl with EBV-associated hemophagocytic lymphohistiocytosis (EBV-HLH) who underwent cord blood (CB) stem cell transplantation (CBSCT) from an unrelated donor. The patient presented with persistent high-grade fever and hepatosplenomegaly. Because the disease was refractory to immunochemotherapy according to the HLH94 protocol, she received 2.0 ؋ 
Hemophagocytic lymphohistiocytosis (HLH) is a lethal disorder of immune dysregulation usually affecting infants and young children. 1 Patients present with fever, hepatosplenomegaly, pancytopenia, coagulopathy and central nervous system (CNS) involvement. 2 HLH has both primary (familial) and secondary (infection-or lymphomaassociated) forms. The management is sometimes quite difficult, and some patients are resistant to chemotherapy with a fatal course, especially those suffering from the familial form. 3 Some cases of EBV-associated HLH (EBV-HLH) also take an aggressive clinical course, 4 although a recent report showed effective control of the majority of EBV-HLH cases given immunochemotherapy with steroids and etoposide. 5 For such cases, hematopoietic stem cell transplantation (SCT) has been performed. Our case report concerns an EBV-HLH patient with a resistant course, who received cord blood (CB) SCT from a 5/6 HLA-matched unrelated donor and recovered.
Materials and methods

EBV DNA studies
The presence of the EBV genome and the clonality of EBV infection was investigated by hybridization of BamHIdigested DNAs to a probe consisting of a 4.6-kb BamHIEcoRI fragment containing tandem terminal repeated sequences of the EBV genome, 6 which provides a virusspecific, clonotypic marker for the pathogenesis of EBVassociated tumors.
For analysis of the EBV subtype, primers specific for type-1 and type-2 EBV were derived from the EBNA 2 gene sequence. 7 A common 5Ј-primer, a type-1-specific 3Ј-primer and a type-2-specific 3Ј-primer were used to amplify products of 249 and 300 bp, respectively. 8 At the end of the amplification cycles, reaction mixtures were analyzed by electrophoresis in 4% agarose gels stained with ethidium bromide and optically visualized by UV transillumination. Specificity of the amplified fragments was confirmed by Southern blot hybridization with type-specific 32 P-labeled oligonucleotide probes.
9 ␤ 2 -microglobulin (␤ 2 -MG) was used as an internal control for each sample, since it is expressed ubiquitously. 10 
Real-time quantitative polymerase chain reaction (PCR) with a fluorogenic probe
The PCR primers for this assay were selected for the BALF5 gene encoding the viral DNA polymerase. 11 The PCR reaction was performed using a Taq-Man PCR kit (PE Applied Biosystems, Branchburg, NJ, USA) and a model 7700 Sequence Detector (PE Applied Biosystems) as previously reported. 11 For a positive control, a plasmid containing the BALF5 gene was constructed with the pGEM-T vector (Promega, Madison, WI, USA) and termed pGEM-BALF5. The virus copy number was calculated automatically with Sequence Detector version 1.6 (PE Applied Biosystems), a software package for data analysis. Each sample was tested in duplicate.
Case report
A 5-year-old girl was referred to our hospital because of persistent high fever and leukocytopenia. There was no past history of illness including in the perinatal period. She was the first-born child of healthy nonconsanguineous parents and had no family history of similar disorders in first or second degree relatives. On physical examination, her body temperature was 40°C. The liver was palpable 1.5 cm below the right costal margin and spleen 4.5 cm below the left costal margin, but there was no lymphadenopathy. Blood examination showed a leukocyte count of 1.4 ϫ 10 9 /l with 1% neutrophils, 74% lymphocytes, 21% monocytes, and 4% atypical lymphocytes. The red cell count was 3500 ϫ 10 9 /l, hemoglobin 95 g/l, and platelet count 238 ϫ 10 9 /l. Blood chemistry showed a total protein of 6.6 (normal 6.7-8.3) g/dl, albumin 3.5 (normal 3.9-5.3) g/dl, lactate dehydrogenase (LDH) 346 (normal 240-470) IU/l, triglyceride 111 (normal 30-150) mg/dl, and C-reactive protein (CRP) 9.7 (control Ͻ0.1) mg/dl. Fibrinogen was 573 (normal 200-400) mg/dl, ferritin 601.5 (normal 8-74) ng/dl, and soluble IL-2 receptor (IL-2R) 6936 (normal 220-530) U/ml. Serological studies for EBV showed titer elevation as follows: VCA IgG 160ϫ, VCA IgM Ͻ10ϫ, VCA IgA Ͻ10ϫ, EA-DR IgG 40ϫ, EA-DR IgA Ͻ10ϫ, and EBNA Ͻ10ϫ. BM examination revealed a proliferation of mature-appearing histiocytes (11.2%) exhibiting active phagocytosis of neutrophils and erythroblasts against a hypoplastic background (nucleated cell count of 22 ϫ 10 9 /l). Central nervous system involvement was not observed on cerebrospinal fluid examination. PCR analysis for EBV genome of peripheral blood and BM mononuclear cells was positive. The amplified product was 249 bp, rather than 300 bp in size, indicating pathological involvement of type-1 EBV in this case. Southern blot hybridization analysis with a probe for the terminal tandem repeats of the EBV genome did not show the presence of definitely clonal bands in the patient's PBMC. The patient was diagnosed as suffering from EBV-associated secondary HLH because of her negative family history. Immunochemotherapy started with dexamethasone and etoposide according to the HLH94 protocol. 12 Although she showed a rapid response to therapy, high fever and hepatosplenomegaly reappeared following steroid dose reduction. She subsequently became resistant to the immunochemotherapy with additional CsA and disease progression was clinically evident with liver dysfunction, jaundice and further elevated levels of ferritin (81433 ng/dl) and soluble IL-2R (27830 U/ml). Satisfactory effects were not obtained with plasma exchange therapy. She developed generalized convulsion presumably due to cyclosporin encephalopathy or CNS involvement of HLH and was placed on mechanical ventilation with intratracheal intubation because of a refractory convulsion itself. Therefore, an immediate search for a suitable stem cell donor was performed and a 5/6 HLA-matched male CB (patient: A*0206, 3101; B*4002, 4006; Cw3; DRB1*0410, 0901; CB: A*0206, Ϫ; B*4002, 4006; Cw4, 8; DRB1*0410, 0901) was available at the Tokai CB Bank (Nagoya, Japan). The conditioning regimen consisted of etoposide (300 mg/m 2 ϫ 3 days), BU (35 mg/m 2 ϫ 4 days), and CY (50 mg/kg ϫ 4 days). The total dose of infused CB cells was 2.0 ϫ 10 7 /kg (nucleated cell number after thawing). The numbers of CFU-GM and CD34 ϩ cells were 1.54 ϫ 10 4 /kg and 5.5 ϫ 10 4 /kg, respectively. For acute GVHD prophylaxis, FK506 (0.03 mg/kg continuous infusion) was employed. Engraftment was achieved on day 21, which was, thereafter, confirmed by male donor karyotype and 99.4% Y-chromosome by FISH analysis on BM examination. Five mitoses obtained from PHA-stimulated peripheral blood cells at the same period also showed a male donor karyotype. The neutrophil count reached Ͼ0.5 ϫ 10 9 /l by day 21, reticulocyte count Ͼ1% by day 40, and platelet count Ͼ50 ϫ 10 9 /l by day 84. Acute GVHD was not apparent. Although on mechanical ventilation, there was no major respiratory infection other than hemorrhagic cystitis due to BK virus infection. Possible relapse of HLH was noted on day ϩ6, characterized by fever and elevation of serum bilirubin, transaminases, ferritin, and soluble IL-2R, which was controlled with intravenous prednisolone (60 mg/day) therapy. At day 24, the patient developed a disturbed consciousness and decreased activity. Although a small intracranial hematoma was found on brain CT scan, FK506 administration was stopped on day 24, because associated encephalopathy could not be excluded. Finally the child recovered with sequelae of neurological deficits, such as amnesia, agnosia, and sensory aphasia, and could be discharged from hospital on day 194 without clinical or serologic evidence of HLH recurrence. She is doing well more than 14 months after CBSCT without any infectious event.
Sequential PBMC samples from the patient were obtained and tested using real-time PCR to estimate the EBV load. As shown in Figure 1 , the EBV DNA copy number decreased as the symptoms resolved after non-relative CBSCT. Concurrently, type-1 EBV positivity could not be detectable from 2 months after the transplantation.
Discussion
We report a patient with refractory EBV-HLH who underwent successful CBSCT from a 5/6 HLA-matched unrelated donor. The disease is very heterogenous with few clinical risk factors that accurately predict responsiveness to immunochemotherapy. 5, 13 Allogeneic bone marrow transplantation, which consistently induces disease resolution and seems to be curative in many cases, has been suggested as the treatment of choice for EBV-HLH. 14, 15 In practice, allogeneic SCT might be required only when recurrent disease develops, since it is possible to control EBV-HLH in a high proportion of cases without resorting to SCT. 5, 16 To our knowledge, this is the first case with EBV-HLH in which CBSCT was successfully performed. As previously reported for successful CBSCT for familial hemophagocytic lymphohistiocytosis (FEL) cases, 17, 18 this approach has potential for control of HLH. However, despite complete hematopoietic and lymphopoietic engraftment, two severe relapses of FEL occurred in earlier cases. 17 Immaturity of infused cord blood lymphocytes might impair the specific immunity, such as immunemediated antileukemia protection. 19, 20 In cases of EBV-HLH, the absence of adoptive transfer of specific immunity toward infectious agents could also contribute to failure to treat the refractory disease. However, as proven in our case, CBSCT appears to be quite effective and cord blood LAK cells may have presumably contributed to lysis of relapsed HLH cells. 21, 22 As shown in Figure 1 , close monitoring with sensitive real-time PCR is very useful to follow the effect of treatment and to detect the relapse of EBV-HLH. In the present case, significant increase and subsequent decrease in EBV copy number was detected in PBMC before and after CBSCT, respectively. This system should be generally applicable for estimation of EBV load in patients with EBV-HLH.
We conclude that application of CB stem cells from nonrelated donors is justified even in EBV-HLH cases. In our Bone Marrow Transplantation patient the preparative regimen and CBSCT were effective at eradicating EBV-HLH and provided durable engraftment. Hematopoietic stem cell transplantation including CBSCT may thus provide an alternative with a better outlook for patients suffering from this aggressive disease.
